Lung Cancer in the Era of Targeted Therapy

Zakowski, Maureen F.
December 2013
Archives of Pathology & Laboratory Medicine;Dec2013, Vol. 137 Issue 12, p1816
Academic Journal
Context.-The diagnosis and treatment of non-small cell lung cancer have changed dramatically in the past few years. The discovery of activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor and the use of drugs that successfully target those mutations are among the key advances that have led to a shift in the practice of oncology and pathology, with perhaps the greatest effect on the field of cytology. Objectives.-To present the perspective of a practicing thoracic pathologist and cytopathologist on the developments that have changed practice and to place those changes in a broader context. Data Sources.-Literature review, studies undertaken or participated in by the author, and personal experience. Conclusions.-Cytologists are in an ideal position to influence appropriate testing and treatment in the era of targeted therapy. Lung pathology has led the way in the era of targeted therapy, in no small part due to cytology.


Related Articles

  • Increased SOX2 Gene Copy Number Is Associated with FGFR1 and PIK3CA Gene Gain in Non-Small Cell Lung Cancer and Predicts Improved Survival in Early Stage Disease. Toschi, Luca; Finocchiaro, Giovanna; Nguyen, Teresa T.; Skokan, Margaret C.; Giordano, Laura; Gianoncelli, Letizia; Perrino, Matteo; Siracusano, Licia; Di Tommaso, Luca; Infante, Maurizio; Alloisio, Marco; Roncalli, Massimo; Scorsetti, Marta; Jänne, Pasi A.; Santoro, Armando; Varella-Garcia, Marileila // PLoS ONE;Apr2014, Vol. 9 Issue 4, p1 

    Background: We aimed to investigate prevalence and prognostic role of SOX2, PIK3CA, FGFR1 and BRF2 gene gain in patients with surgically resected non-small cell lung cancer (NSCLC). Methods: SOX2, PIK3CA, FGFR1 and BRF2 gene copy number was assessed by fluorescence in situ hybridization (FISH)...

  • A Rational Diagnostic Algorithm for the Identification of ALK Rearrangement in Lung Cancer: A Comprehensive Study of Surgically Treated Japanese Patients. Takamochi, Kazuya; Takeuchi, Kengo; Hayashi, Takuo; Oh, Shiaki; Suzuki, Kenji // PLoS ONE;Aug2013, Vol. 8 Issue 8, p1 

    Background: EML4-ALK fusion gene is found in only a small subset (2–6%) of non-small cell lung cancer. There is an urgent need to establish a rational diagnostic algorithm to identify this rare but important fusion in lung cancer. Methods: We performed a comprehensive analysis of...

  • Epidermal growth factor receptor mutations in nonsmall cell lung carcinoma patients in Kuwait. AL-TEMAIMI, RABEAH; KAPILA, KUSUM; AL-MULLA, FAHD R.; FRANCIS, ISSAM M.; AL-WAHEEB, SALAH; AL-AYADHY, BUSHRA // Journal of Cytology;Jan-Mar2016, Vol. 33 Issue 1, p1 

    Context: Nonsmall cell lung carcinoma (NSCLC) is the most frequently diagnosed form of lung cancer in Kuwait. NSCLC samples from Kuwait have never been screened for epidermal growth factor receptor (EGFR) gene aberration, which is known to affect treatment options. Aims: This study investigated...

  • Capturing Genomic Evolution of Lung Cancers through Liquid Biopsy for Circulating Tumor DNA. Offin, Michael; Chabon, Jacob J.; Razavi, Pedram; Isbell, James M.; Rudin, Charles M.; Diehn, Maximilian; Li, Bob T. // Journal of Oncology;3/14/2017, p1 

    Genetic sequencing of malignancies has become increasingly important to uncover therapeutic targets and capture the tumor’s dynamic changes to drug sensitivity and resistance through genomic evolution. In lung cancers, the current standard of tissue biopsy at the time of diagnosis and...

  • Modified Histologic Classification as a Prognostic Factor in Pulmonary Adenocarcinoma. Hwang, Ilseon; Park, Keon Uk; Kwon, Kun Young // International Journal of Surgical Pathology;May2014, Vol. 22 Issue 3, p212 

    Background. The histologic pattern of pulmonary adenocarcinoma is highly heterogeneous and considered to be an important prognostic factor. The predominant histologic pattern is emphasized in the 2011 International Association for the Study of Lung Cancer, American Thoracic Society, and European...

  • Identification of featured biomarkers in different types of lung cancer with DNA microarray. Zhou, Chao; Chen, Hao; Han, Li; Wang, An; Chen, Liang-an // Molecular Biology Reports;Oct2014, Vol. 41 Issue 10, p6357 

    Lung cancer is a worldwide leading cause of cancer-related death. The aim of this study was to identify target genes and specific biomarkers for identification and treatment of different types of lung cancer with DNA microarray. Gene expression profile GSE6044 and miRNA microarray profile...

  • Screening feature genes of lung carcinoma with DNA microarray analysis. Liangdong Chen; Deqiang Zhuo; Jiakuan Chen; Hongyin Yuan // International Journal of Clinical & Experimental Medicine;2015, Vol. 8 Issue 8, p12161 

    Lung carcinoma is the most common and aggressive malignant tumor with poor clinical outcome. Identification of new marker of lung cancer is essential for the diagnosis and prognosis of the disease. To identify differentially expressed genes (DEGs) and find associated pathways that may function...

  • Education: Viewpoint - Screening for lung cancer.  // GP: General Practitioner;3/31/2014, p16 

    Dr David Simcock discusses the role of EBUS in lung cancer screening.

  • Five microRNAs in plasma as novel biomarkers for screening of early-stage non-small cell lung cancer. Qing Geng; Tao Fan; Boyou Zhang; Wei Wang; Yao Xu; Hao Hu // Respiratory Research;2014, Vol. 15 Issue 11, p1 

    Background: In order to find novel noninvasive biomarkers with high accuracy for the screening of early-stage non-small cell lung cancer (NSCLC), we investigate the predictive power of 5 microRNAs (miR-20a, miR-145, miR-21, miR223 and miR-221) as potential biomarkers in early-stage NSCLC....


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics